Adrenocortical Carcinoma: Impact of Surgical Margin Status on Long-Term Outcomes

Annals of Surgical Oncology

Volumn 23, Issue 1, 2016, Pages 134-141

  Margonis, Georgios Antonios ^a   Kim, Yuhree ^a   Prescott, Jason D ^a   Tran, Thuy B ^b   Postlewait, Lauren M ^c   Maithel, Shishir K ^c   Wang, Tracy S ^d   Evans, Douglas B ^d   Hatzaras, Ioannis ^e   Shenoy, Rivfka ^e   Phay, John E ^f   Keplinger, Kara ^f   Fields, Ryan C ^g   Jin, Linda X ^g   Weber, Sharon M ^h   Salem, Ahmed ^h   Sicklick, Jason K ⁱ   Gad, Shady ⁱ   Yopp, Adam C ^j   Mansour, John C ^j   Duh, Quan Yang ^k   Seiser, Natalie ^k   Solorzano, Carmen C ^l   Kiernan, Colleen M ^l   Votanopoulos, Konstantinos I ^m   Levine, Edward A ^m   Poultsides, George A ^b   Pawlik, Timothy M ^a   more..

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d MEDICAL COLLEGE OF WISCONSIN   (United States)

^e NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f OHIO STATE UNIVERSITY   (United States)

^g WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

ⁱ UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^j UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^k UNIVERSITY OF CALIFORNIA   (United States)

^l VANDERBILT UNIVERSITY   (United States)

^m WAKE FOREST SCHOOL OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

MITOTANE;

ADRENAL CORTEX CARCINOMA; ADULT; AGE; ARTICLE; BODY MASS; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER RECURRENCE; CANCER SIZE; CANCER SURGERY; CANCER SURVIVAL; DISEASE SEVERITY; FEMALE; GENDER; HEMISPHERIC DOMINANCE; HORMONE RELEASE; HUMAN; LONG TERM SURVIVAL; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT SELECTION; POSTOPERATIVE CARE; POSTOPERATIVE HEMORRHAGE; RECURRENCE FREE SURVIVAL; TREATMENT OUTCOME; TUMOR INVASION; ADRENAL CORTEX NEOPLASMS; ADRENOCORTICAL CARCINOMA; CANCER STAGING; CLINICAL TRIAL; COHORT ANALYSIS; FOLLOW UP; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; POSTOPERATIVE COMPLICATION; PROGNOSIS; SURVIVAL RATE; TUMOR RECURRENCE;

ADRENAL CORTEX NEOPLASMS; ADRENOCORTICAL CARCINOMA; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; POSTOPERATIVE COMPLICATIONS; PROGNOSIS; SURVIVAL RATE;

EID: 84952628982     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-015-4803-x     Document Type: Article

References (42)

1. Kebebew E, Reiff E, Duh QY, Clark OH, McMillan A. Extent of disease at presentation and outcome for adrenocortical carcinoma: have we made progress? World JSurg. 2006;30:872–8.
2. Kerkhofs TM, Verhoeven RH, Van der Zwan JM, Dieleman J, Kerstens MN, Links TP, et al. Adrenocortical carcinoma: a population-based study on incidence and survival in the Netherlands since 1993. Eur JCancer. 2013;49:2579–86.
3. Custodio G, Parise GA, Kiesel Filho N, Komechen H, Sabbaga CC, Rosati R, et al. Impact of neonatal screening and surveillance for the TP53 R337H mutation on early detection of childhood adrenocortical tumors. J Clin Oncol. 2013;31:2619–26.
4. Stratakis CA. Adrenal cancer in 2013: Time to individualize treatment for adrenocortical cancer? Nat Rev Endocrinol. 2014;10:76–8.
5. Bougeard G, Sesboue R, Baert-Desurmont S, Vasseur S, Martin C, Tinat J, et al. Molecular basis of the Li-Fraumeni syndrome: an update from the French LFS families. J Med Genet. 2008;45:535–8.
6. Gatta-Cherifi B, Chabre O, Murat A, Niccoli P, Cardot-Bauters C, Rohmer V, et al. Adrenal involvement in MEN1. Analysis of 715 cases from the Groupe d’etude des Tumeurs Endocrines database. Eur J Endocrinol. 2012;166:269–79.
7. Lapunzina P. Risk of tumorigenesis in overgrowth syndromes: a comprehensive review. Am J Med Genet C Semin Med Genet. 2005;137C:53–71.
8. Medina-Arana V, Delgado L, Gonzalez L, Bravo A, Díaz H, Salido E, et al. Adrenocortical carcinoma, an unusual extracolonic tumor associated with Lynch II syndrome. Fam Cancer. 2011;10:265–71.
9. Morin E, Mete O, Wasserman JD, Joshua AM, Asa SL, Ezzat S. Carney complex with adrenal cortical carcinoma. J Clin Endocrinol Metab. 2012;97:E202–6.
10. Raymond VM, Everett JN, Furtado LV, Gustafson SL, Jungbluth CR, Gruber SB, et al. Adrenocortical carcinoma is a lynch syndrome-associated cancer. J Clin Oncol. 2013;31:3012–8.
11. Ayala-Ramirez M, Jasim S, Feng L, Ejaz S, Deniz F, Busaidy N, et al. Adrenocortical carcinoma: clinical outcomes and prognosis of 330 patients at a tertiary care center. Eur J Endocrinol. 2013;169:891–9.
12. Livhits M, Li N, Yeh MW, Harari A. Surgery is associated with improved survival for adrenocortical cancer, even in metastatic disease. Surgery. 2014;156:1531–40; discussion 1540-1.
13. Mihai R. Diagnosis, treatment and outcome of adrenocortical cancer. Br J Surg. 2015;102:291–306.
14. Ronchi CL, Kroiss M, Sbiera S, Deutschbein T, Fassnacht M. EJE prize 2014: current and evolving treatment options in adrenocortical carcinoma: where do we stand and where do we want to go? Eur J Endocrinol. 2014;171:R1-11.
15. Fassnacht M, Johanssen S, Quinkler M, Bucsky P, Willenberg HS, Beuschlein F, et al. Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma: proposal for a Revised TNM Classification. Cancer. 2009;115:243–50.
16. Beuschlein F, Weigel J, Saeger W, Kroiss M, Wild V, Daffara F, et al. Major prognostic role of Ki67 in localized adrenocortical carcinoma after complete resection. J Clin Endocrinol Metab. 2015;100:841–9.
17. Bilimoria KY, Shen WT, Elaraj D, Bentrem DJ, Winchester DJ, Kebebew E, et al. Adrenocortical carcinoma in the United States: treatment utilization and prognostic factors. Cancer. 2008;113:3130–6.
18. Else T, Williams AR, Sabolch A, Jolly S, Miller BS, Hammer GD. Adjuvant therapies and patient and tumor characteristics associated with survival of adult patients with adrenocortical carcinoma. J Clin Endocrinol Metab. 2014;99:455–61.
19. Ip JC, Pang TC, Glover AR, Soon P, Clarke S, Richardson A, et al. Improving outcomes in adrenocortical cancer: an Australian perspective. Ann Surg Oncol. 2014;22(7):2309–16.
20. de Haas RJ, Wicherts DA, Flores E, Azoulay D, Castaing D, Adam R. R1 resection by necessity for colorectal liver metastases: is it still a contraindication to surgery? Ann Surg. 2008;248:626–37.
21. Margonis GA, Spolverato G, Kim Y, Ejaz A, Pawlik TM. Intraoperative surgical margin re-resection for colorectal liver metastasis: is it worth the effort? J Gastrointest Surg. 2015;19:699–707.
22. Abdel-Wahab M, El-Husseiny TS, El Hanafy E, El Shobary M, Hamdy E. Prognostic factors affecting survival and recurrence after hepatic resection for hepatocellular carcinoma in cirrhotic liver. Langenbecks Arch Surg. 2010;395:625–32.
23. Schiffman SC, Woodall CE, Kooby DA, Martin RC, Staley CA, Egnatashvili V, et al. Factors associated with recurrence and survival following hepatectomy for large hepatocellular carcinoma: a multicenter analysis. J Surg Oncol. 2010;101:105–10.
24. Khan MA, Hakeem AR, Scott N, Saunders RN. Significance of R1 resection margin in colon cancer resections in the modern era. Colorectal Dis. 2015. doi:10.1111/codi.12960.
25. Loncar Z, Djukic V, Zivaljevic V, Pekmezovic T, Diklic A, Tatic S, et al. Survival and prognostic factors for adrenocortical carcinoma: a single institution experience. BMC Urol. 2015;15:43.
26. Wanis KN, Kanthan R. Diagnostic and prognostic features in adrenocortical carcinoma: a single-institution case series and review of the literature. World J Surg Oncol. 2015;13:117.
27. Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240:205–13.
28. Miller BS, Doherty GM. Surgical management of adrenocortical tumours. Nat RevEndocrinol. 2014;10:282–92.
29. Hwang EC, Hwang I, Jung SI, Kang TW, Kwon DD, Heo SH, et al. Prognostic factors for recurrence-free and overall survival after adrenalectomy for metastatic carcinoma: a retrospective cohort pilot study. BMC Urol. 2014;14:41.
30. Grubbs EG, Callender GG, Xing Y, Perrier ND, Evans DB, Phan AT, et al. Recurrence of adrenal cortical carcinoma following resection: surgery alone can achieve results equal to surgery plus mitotane. AnnSurg Oncol. 2010;17:263–70.
31. Leboulleux S, Deandreis D, Al Ghuzlan A, Aupérin A, Goéré D, Dromain C, et al. Adrenocortical carcinoma: is the surgical approach a risk factor of peritoneal carcinomatosis? Eur J Endocrinol. 2010;162:1147–53.
32. Lombardi CP, Raffaelli M, De Crea C, Boniardi M, De Toma G, Marzano LA, et al. Open versus endoscopic adrenalectomy in the treatment of localized (stage I/II) adrenocortical carcinoma: results of a multiinstitutional Italian survey. Surgery. 2012;152:1158–64.
33. Porpiglia F, Garrone C, Giraudo G, Destefanis P, Fontana D, Morino M. Transperitoneal laparoscopic adrenalectomy: experience in 72 procedures. J Endourol. 2001;15:275–9.
34. Weiss LM. Comparative histologic study of 43 metastasizing and nonmetastasizing adrenocortical tumors. Am J Surg Pathol. 1984;8:163–9.
35. Chen HW, Liao S, Lau WY, Wang FJ, Deng FW, Lai EC, et al. Prognostic impact of hepatic resection for hepatocellular carcinoma: the role of the surgeon in achieving R0 resection–a retrospective cohort study. Int J Surg. 2015;13:297–301.
36. Lang H, Sotiropoulos GC, Sgourakis G, Schmitz KJ, Paul A, Hilgard P, et al. Operations for intrahepatic cholangiocarcinoma: single-institution experience of 158 patients. J Am Coll Surg. 2009;208:218–28.
37. Paik KY, Jung JC, Heo JS, Choi SH, Choi DW, Kim YI. What prognostic factors are important for resected intrahepatic cholangiocarcinoma? J Gastroenterol Hepatol. 2008;23:766–70.
38. Pawlik TM, Scoggins CR, Zorzi D, Abdalla EK, Andres A, Eng C, et al. Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases. Ann Surg. 2005;241:715–22, discussion 722-4.
39. Takahashi S, Doss C, Levy S, Levy R. TAPA-1, the target of an antiproliferative antibody, is associated on the cell surface with the Leu-13 antigen. J Immunol. 1990;145:2207–13.
40. Gaujoux S, Brennan MF. Recommendation for standardized surgical management of primary adrenocortical carcinoma. Surgery. 2012;152:123–32.
41. Reibetanz J, Jurowich C, Erdogan I, Nies C, Rayes N, Dralle H, et al. Impact of lymphadenectomy on the oncologic outcome of patients with adrenocortical carcinoma. Ann Surg. 2012;255:363–9.
42. Saade N, Sadler C, Goldfarb M. Impact of regional lymph node dissection on disease specific survival in adrenal cortical carcinoma. Horm Metab Res. 2015.